Kiniksa Pharmaceuticals International PLC
KNSA
Company Profile
Business description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Contact
23 Old Bond Street
Floor 3
LondonW1S 4PZ
GBRT: +44 7814319100
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
315
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
Our latest stock pitch.
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Market reacts positively to results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,907.00 | 2.50 | 0.03% |
| CAC 40 | 8,157.79 | 74.70 | -0.91% |
| DAX 40 | 23,839.95 | 201.67 | -0.84% |
| Dow JONES (US) | 47,172.77 | 284.45 | -0.60% |
| FTSE 100 | 9,683.59 | 124.09 | -1.27% |
| HKSE | 26,572.46 | 500.57 | -1.85% |
| NASDAQ | 22,958.06 | 87.71 | 0.38% |
| Nikkei 225 | 50,376.53 | 905.30 | -1.77% |
| NZX 50 Index | 13,464.46 | 207.27 | -1.52% |
| S&P 500 | 6,744.81 | 7.32 | 0.11% |
| S&P/ASX 200 | 8,634.50 | 8.90 | 0.10% |
| SSE Composite Index | 3,990.49 | 39.01 | -0.97% |